Article Details
Retrieved on: 2025-07-28 14:51:33
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
ONC-841 is a first-in-class, clinical stage anti-SIGLEC 10 monoclonal antibody currently under development for the treatment of both solid tumors and ...
Article found on: pipelinereview.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here